-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IDuHax12MFmPecWkslVM7XDRll8vF+mvoZeI1Xob3YwH8ReSR0P6VwVQiBWAmO+q IQPzpWGwrElEGTs6h0ttaw== 0001144204-07-031799.txt : 20070614 0001144204-07-031799.hdr.sgml : 20070614 20070614104248 ACCESSION NUMBER: 0001144204-07-031799 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070430 FILED AS OF DATE: 20070614 DATE AS OF CHANGE: 20070614 EFFECTIVENESS DATE: 20070614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMAZON BIOTECH INC CENTRAL INDEX KEY: 0001088781 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870416131 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26753 FILM NUMBER: 07919023 BUSINESS ADDRESS: STREET 1: 43 WEST 33RD STREET STREET 2: SUITE 405 CITY: NEW YORK STATE: NY ZIP: 84107 BUSINESS PHONE: (212) 695-3003 MAIL ADDRESS: STREET 1: 43 WEST 33RD STREET STREET 2: SUITE 405 CITY: NEW YORK STATE: NY ZIP: 84107 FORMER COMPANY: FORMER CONFORMED NAME: ASYST CORP DATE OF NAME CHANGE: 19990615 NT 10-Q 1 v078404_nt10-q.txt ------------------------ (Check One) UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION ------------------------ |_| Form 10-K Washington, D.C. 20549 OMB Number: 3235-0058 |_| Form 20-F Expires: April 30, 2009 |_| Form 11-K FORM 12b-25 Estimated average burden |X| Form 10-Q hours per response ... |_| Form 10-D NOTIFICATION OF LATE FILING 2.50 |_| Form N-SAR ------------------------ |_| Form N-CSR SEC FILE NUMBER 000-26753 ------------------------ ------------------------ For Period Ended: April 30, 2007. |_| Transition Report on Form 10-K |_| Transition Report on Form 20-F |_| Transition Report on Form 11-K |_| Transition Report on Form 10-Q |_| Transition Report on Form N-SAR For the Transition Period Ended: ________________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: - -------------------------------------------------------------------------------- PART I - REGISTRANT INFORMATION Amazon Biotech, Inc. ------------------------------------------------------------- Full Name of Registrant ASYST CORP ------------------------------------------------------------- Former Name if Applicable 43 West 33rd Street ------------------------------------------------------------- Address of Principal Executive Office (Street and Number) New York, NY 10001 ------------------------------------------------------------- City, State and Zip Code - -------------------------------------------------------------------------------- PART II - RULES 12b-25(b) AND (c) If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense. (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or |X| portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filled on or before the fifth calendar day following the prescribed due date: and (c) The accountant's statement or other exhibit is required by Rule 12b-25(c) has been attached if applicable. - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- PART III - NARRATIVE State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach Extra Sheets if Needed) The Company could not complete the filing of its Quarterly Report on Form 10-QSB for the quarter ended April 30, 2007 due to a delay in obtaining and compiling information required to be included in the Company's Form 10-QSB, which delay could not be eliminated by the Company without unreasonable effort and expense. Such delay was primarily the result of completing the detailed financial statements. The Company intends to file its Quarterly Report on Form 10-Q as soon as practicable after the completion of the review by its officers and directors. - -------------------------------------------------------------------------------- PART IV - OTHER INFORMATION (1) Name and telephone number of person to contact in regard to this notification Mechael Kanovsky (212) 947-3362 - -------------------------------- -------------------- ---------------------- (Name) (Area Code) (Telephone Number) (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). Yes |X| No |_| (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes |_| No |X| If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. - -------------------------------------------------------------------------------- Amazon Biotech, Inc. -------------------------------------------- (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 14, 2007 By: /s/ Mechael Kanovsky ----------------------------------- Mechael Kanovsky Chief Executive Officer -----END PRIVACY-ENHANCED MESSAGE-----